title: The effects of angiotensin peptides and angiotensin receptor antagonists on the cell growth and angiogenic activity of GH3 lactosomatotroph cells in vitro.
abstract: The local renin-angiotensin system (RAS) is present in the pituitary gland, and inhibitory effects of angiotensins on the lactosomatotroph (GH3) cell growth have been revealed. The aim of this study was to examine the influence of various angiotensin peptides and angiotensin AT1, AT2, and AT4 receptors antagonists on the cell proliferation, viability, and VEGF secretion in pituitary lactosomatotroph GH3 cell culture in order to identify receptors involved in antiproliferative effects of angiotensins on GH3 tumor cells. Cell viability and proliferation using Mosmann method and BrdU incorporation during DNA synthesis, and VEGF secretion using ELISA assay were estimated. The inhibitory effects of ang II, ang IV, and ang 5-8 on the cell viability and BrdU incorporation in GH3 culture were not abolished by AT1, AT2, and AT4 receptors antagonists. Ang II, as well as ang III and ang IV at lower concentrations stimulated the secretion of VEGF in GH3 cell culture. The secretion of VEGF was inhibited by ang III and ang IV at higher concentrations. AT1 and AT2 receptors antagonists prevented the proangiogenic effects of ang II. Ang II, ang IV, and ang 5-8 decrease the cell number and proliferation in GH3 cell culture independently of the AT1, AT2, and AT4 receptors. These peptides affect also secretion of VEGF in culture examined. Both the AT1 and AT2 receptors appear to mediate the proangiogenic effects of ang II.
authors.affiliation: Department of Endocrinology, The County Hospital of Kutno, 52 Kosciuszki Street, 99-300, Kutno, Poland.
authors.forename: Dorota
authors.initials: D
authors.lastname: Ptasinska-Wnuk
authors.forename: Slawomir A
authors.initials: SA
authors.lastname: Mucha
authors.forename: Hanna
authors.initials: H
authors.lastname: Lawnicka
authors.forename: Jolanta
authors.initials: J
authors.lastname: Fryczak
authors.forename: Jolanta
authors.initials: J
authors.lastname: Kunert-Radek
authors.forename: Marek
authors.initials: M
authors.lastname: Pawlikowski
authors.forename: Henryk
authors.initials: H
authors.lastname: Stepien
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology*; D000809:Angiotensins / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D007093:Imidazoles / Q000494:pharmacology; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010446:Peptide Fragments / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D052683:Somatotrophs / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D043925:Angiogenesis Inducing Agents; D057911:Angiotensin Receptor Antagonists; D000809:Angiotensins; D007093:Imidazoles; D010446:Peptide Fragments; D011725:Pyridines; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; C073402:PD 123319